PCSK9 inhibitors likely to remain as injectables


Reports this week that Pfizer intends to shelve the development of its oral PCSK9 inhibitor suggest the future of this therapy may remain in injectables. In its Q2 earnings report earlier this week Pfizer President Mikael Dolston said: “We don’t think that the oral PCSK9 profile would be competitive with the strong LDL lowering seen with ...


Already a member? Login to keep reading


OR
© 2017 the limbic